Regeneron publishes data supporting Ab cocktail as passive COVID-19 vaccine

By The Science Advisory Board staff writers

January 26, 2021 -- Regeneron said that interim data from its ongoing phase III clinical trial supports the use of its Regen-CoV antibody (Ab) cocktail as a passive vaccine for preventing COVID-19.

In an exploratory analysis conducted on the first approximately 400 evaluable individuals enrolled in the phase III trial, the researchers found that passive vaccination with Regen-CoV resulted in 100% prevention of symptomatic COVID-19 infection and approximately 50% lower overall rates of infection than those who had received only placebo, Regeneron said. What's more, those who had received Regen-CoV and had asymptomatic infections experienced markedly decreased levels and duration of viral shedding.

Infections in the placebo group had an average of more than 100-fold higher peak load. Furthermore, infections in the Regen-CoV group lasted no more than one week, while about 40% of infections in the placebo group lasted three to four weeks, Regeneron said. None of the infected individuals in the Regen-CoV group had high viral loads, compared with 62% of the infected placebo group, according to the firm.

The trial is being run jointly by Regeneron with the U.S. National Institute of Allergy and Infectious Diseases (NIAID). The company said it expects to have confirmatory phase III results in the second quarter.

Copyright © 2021
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here